Pathways to Antimicrobial Clinical Efficacy. Accelerating and strengthening the pre-clinical AMR pipeline. @LifeArc1 | @InnovateUK | @MedDiscCat
UK
Joined June 2023
- Tweets136
- Following60
- Followers142
- Likes301
We are delighted to welcome Dr Dan Zurawski of @genevaUSA and Triari Pharmaceuticals into the #PACEPortfolio. Dan and his team are developing human monoclonal antibodies targeting 饾槇饾槫饾槳饾槸饾槮饾樀饾槹饾槪饾槩饾槫饾樀饾槮饾槼 饾槪饾槩饾樁饾槷饾槩饾槸饾槸饾槳饾槳.
PACE will support The Geneva Foundation and Triari Pharmaceuticals to generate the critical data packages needed to position them for onward funding and investment .
Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
PACE will support The Geneva Foundation and Triari Pharmaceuticals to generate the critical data packages needed to position them for onward funding and investment .
Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
We are at ESCMID Global 2025 in Vienna, Austria! R&D Advisors, Lisa Dawson and Jon Gibson, are representing PACE, so please do talk to them and find out what we are doing to support the AMR R&D community.
#ESCMIDGlobal2025
馃數 Our Programme Director, Dr Beverley Isherwood was recently interviewed by Helen Albert for Inside Precision Medicine. Read about how PACE is supporting early-stage innovation to help tackle AMR.
eu1.hubs.ly/H0j970n0
#AMR
@MedDiscCat | @innovateuk | @lifearc1
Congratulations to @immunethep!
We are delighted to announce that Immunethep has joined the PACE portfolio. Immunethep is advancing monoclonal antibodies to restore the ability to control bacterial infection. (1/2)
(2/2) Through access to expertise and enabling capabilities, we will support Immunethep to progress their asset towards the clinic. Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
Meet our PACE Delivery Partners! Innovators require support to accelerate antimicrobial & diagnostic discovery. Our Delivery Partner Network (DPN) connects providers with innovators to help with outsourced work & advice for PACE-funded projects.
馃敆: eu1.hubs.ly/H0hkL-Q0
(1/2)
馃數 This week, #PACE is at the 9th #AMRConference in Switzerland, connecting with global innovators and hearing from great speakers. If you're attending visit us at exhibition booth 1 to learn about our work tackling #AMR. Thanks to organisers @AllianceBEAM and bamconn GmbH.
It is a pleasure to welcome @IneosOxford (IOI) for #AntimicrobialResearch into the #PACEPortfolio. IOI is optimising a new class of broad-spectrum cell wall transpeptidase inhibitors.
By supporting organisations such as IOI, we aim to maximise the success of leading antimicrobial innovations, accelerating project development with greater speed and confidence.
Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
We are thrilled to welcome @OxDrugDes as the latest member of the #PACEPortfolio. Oxford Drug Design is progressing small molecule, locally-acting enzyme inhibitors for oral therapy of urinary tract infections.
We look forward to supporting Oxford Drug Design to advance their asset by offering guidance, mentorship, and access to enabling tools and technologies.
Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
#AMR
We are delighted to be attending next week鈥檚 #AMRConference: Novel Antimicrobials and AMR Diagnostics. We have a space in the exhibition area (booth number 1), so please stop by to find out how PACE is supporting early-stage innovation to tackle AMR.
馃敆 eu1.hubs.ly/H0gWjgP0
Congratulations to PhalconBio!
We are delighted to announce that PhalconBio has joined the #PACEPortfolio. PhalconBio is advancing dual-action, inhalable phage treatments for bronchiectasis-associated 饾槜饾槾饾槮饾樁饾槬饾槹饾槷饾槹饾槸饾槩饾槾 饾槩饾槮饾槼饾樁饾槰饾槳饾槸饾槹饾槾饾槩 infections.
Through access to mentors, advisors and enabling capabilities, PACE will support PhalconBio to progress its innovative technology towards the clinic.
Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
It鈥檚 a pleasure to welcome Professor Till Sch盲berle of @jlugiessen University Giessen in partnership with @INFEX_TX, to the PACE portfolio. As collaborators they are optimising a membrane-targeting bicyclic heptapeptide for treatment of Gram-negative infections.
We look forward to working together to move their project closer to the clinic, and ultimately bring new antibiotics to tackle the major global health challenge that is #AMR.
Find out more about the project by visiting our Portfolio page: paceamr.org.uk/portfolio/
馃數 PACE at #BioInfect2025 in Liverpool. Dr. Beverley Isherwood and Dr. Phil Packer have been speaking about our work supporting early-stage projects, our enabling collaborations and our role in funding #AMR R&D.
@Bionow
